Circulating Tumor DNA in Peripheral T-cell Lymphomas
Conditions: Peripheral T-cell Lymphoma; NK/T-Cell Lymphoma Interventions: Diagnostic Test: Tumor-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay; Diagnostic Test: 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) Sponsors: University of Aarhus; Aarhus University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

Chimeric antigen receptor treatment targeting cd70 (seventy)
Conditions: Leukemia, Myeloid, Acute; Leukemia, B-cell; Leukemia, T-Cell; Lymphoma Interventions: Biological: Treatment Arm A Sponsors: Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Interventions: Drug: Sintilimab+Pegaspargase; Drug: P-GemOx; Drug: GELAD; Radiation: IMRT Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or S ézary Syndrome Previously Treated With Systemic Therapy
Conditions: Cutaneous T-Cell Lymphoma Interventions: Drug: Mogamulizumab Sponsors: Kyowa Kirin China Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
Conditions: Extranodal Natural Killer T Cell Lymphoma Interventions: Drug: chidamide, anti-PD1 antibody, and pegaspargase; Drug: DDGP Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
BURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 8, 2024 Category: Pharmaceuticals Source Type: clinical trials

GVM ±R in Patients With Relapsed or Refractory Aggressive NHL.
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B-cell Lymphoma Interventions: Drug: GVM ±R regimen Sponsors: Qiu Lugui Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Conditions: T-cell Lymphoma Interventions: Biological: hNeo-T; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: BGI, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL
Conditions: Angioimmunoblastic T-cell Lymphoma Interventions: Drug: mitoxantrone liposome 16 and azacitidine; Drug: mitoxantrone liposome 18 and azacitidine; Drug: mitoxantrone liposome 20 and azacitidine Sponsors: Huijing Wu; Beijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Chi-GVM Regimen for the Treatment of R/R PTCL
Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma Interventions: Drug: Chi-GVM Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Conditions: CD30-Positive Diffuse Large B-Cell Lymphoma; Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type; Anaplastic Large Cell Lymphoma, ALK-Positive; Peripheral T-cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative; Non-Hodgkin Lymphoma; Hodgkin Lymphoma Interventions: Biological: C7R.CD30.CAR-EBVST cells Sponsors: Baylor College of Medicine; The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma
Conditions: Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma Interventions: Drug: Azacytidine plus CAOLD regimen Sponsors: Navy General Hospital, Beijing; Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 19, 2023 Category: Research Source Type: clinical trials

A Study of SHR2554 With Chemotherapy in Treatment-na ïve Patients With Peripheral T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma Interventions: Drug: SHR2554/CHOP; Drug: SHR2554/CHOEP Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma Interventions: Drug: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Sponsors: National Cancer Centre, Singapore; Merck Sharp& Dohme LLC; National Medical Research Council (NMRC), Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Conditions: Peripheral T Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma; Refractory T-Cell Lymphoma Interventions: Drug: Chidamide combined with Duvillisib Sponsors: The First Affiliated Hospital of Xiamen University; Fujian Cancer Hospital; Zhangzhou Affiliated Hospital of Fujian Medical University; Dongguan People ' s Hospital; Huizhou Municipal Central Hospital; The First Affiliated Hospital with Nanjing Medical University; Sun Yat-sen University; Shanxi Province Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials